210 results on '"Campos, Susana M."'
Search Results
2. Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC).
3. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
4. A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies
5. Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors
6. Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.
7. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
8. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect
9. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024
10. Leveraging Evolving Data Sets on PARP Inhibitors in Ovarian Cancer to Inform Treatment Decision-making
11. Vulvar Yolk Sac Tumors Are Somatically Derived SMARCB1 (INI-1)-Deficient Neoplasms
12. Surveillance Imaging in Patients With Endometrial Cancer in First Remission
13. Validation of an open-source smartphone step counting algorithm in clinical and non-clinical settings
14. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions
15. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
16. Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma
17. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study
18. Stage 1 results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas (NCT03355976).
19. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma
20. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
21. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
22. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
23. Safety of Bevacizumab in Advanced Ovarian and Müllerian Cancers: A Review
24. A Comparative Study of Exemestane Versus Anastrozole in Patients with Postmenopausal Breast Cancer with Visceral Metastases
25. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021
26. Vulvar Yolk Sac Tumors Are Somatically Derived SMARCB1 (INI-1)-Deficient Neoplasms
27. Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer
28. A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
29. EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.
30. A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC).
31. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma
32. Evolving treatment approaches for early breast cancer
33. Breast Cancer
34. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020
35. A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma.
36. Patient-reported and clinician-rated performance status and general health among women with gynecologic cancers on palliative chemotherapy.
37. Anti-Epidermal Growth Factor Receptor Strategies for Advanced Breast Cancer
38. Role of pegylated liposomal doxorubicin in ovarian cancer
39. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases
40. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies
41. Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm
42. Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer
43. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Mullerian tumors
44. Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
45. Ofranergene obadenovec (VB-111) in platinum resistant ovarian cancer: with an immunotherapeutic effect.
46. Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC).
47. Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.
48. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
49. Spigelian Hernia
50. The Clinical Utility of Liposomal Doxorubicin in Recurrent Ovarian Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.